A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199) (SIRTA)
This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
First received: August 2, 2011
Last updated: December 15, 2011
Last verified: December 2011
The purpose of this study is to collect information of the risk profile of patients with type 2 diabetes mellitus, their treatment concerning meeting the guidelines for treatment of diabetic patients type 2 published by the Deutsche Diabetes Gesellschaft (DDG) on October 13, 2008
||Observational Model: Cohort
Time Perspective: Prospective
||Standardized Non-interventional Register Investigating the Daily Clinical Practice for the Treatment of Patients With Diabetes Mellitus Type 2 (SIRTA)
Primary Outcome Measures:
- Change From Baseline for Mean Hemoglobin A1c (HbA1C) [ Time Frame: Baseline and end of Observation (up to Month 6) ] [ Designated as safety issue: No ]
Change from baseline was defined as mean HbA1c baseline value minus the mean HbA1c end of observation value.
- Change From Baseline for Mean Fasting Blood Glucose (FBG) [ Time Frame: Baseline and end of Observation (up to Month 6) ] [ Designated as safety issue: No ]
Change from baseline was defined as mean FBG baseline value minus mean FBG end of observation value.
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||January 2011 (Final data collection date for primary outcome measure)
All Enrolled Participants
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Participants with type 2 diabetes mellitus being treated in an office setting with metformin at the individual maximal tolerated dose (at least four weeks on stable dose) and had a resultant HbA1c >6.5% were selected for this study. The first five eligible participants per site with type 2 diabetes mellitus and treatment with metformin were to be enrolled.
- Newly diagnosed with Type 2 diabetes in whom treatment with metformin in the individual maximal tolerated dose (at least four weeks on stable dose) resulted in HbA1c >6.5%
- No contraindication or intolerability to metformin
- Currently being administered a combination therapy for the treatment of their Type 2 diabetes
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
No Contacts or Locations Provided
No publications provided
||Merck Sharp & Dohme Corp.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||August 2, 2011
|Results First Received:
||December 15, 2011
||December 15, 2011
||Germany: The Bavarian State Ministry of the Environment and Public Health
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 28, 2014
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Endocrine System Diseases